Cangene Corporation has entered into an agreement with a Swedish company, Camurus AB, for exclusive rights to commercialize Episil in the United States.
The drug is used for the management and relief of pain associated with oral lesions, including oral mucositis (OM), which results from cancer therapy and other causes.
Cangene plans to launch Episil in the U.S. in October 2012.
Headquartered in Winnipeg, Cangene’s products are sold worldwide and include products that have been accepted into the U.S. Strategic National Stockpile. It operates manufacturing facilities in Winnipeg and Baltimore and three U.S. and one Canadian plasma-collection facilities operating under the name Cangene Plasma Resources.